

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

Ba/F3

RRID:CVCL_0161

Type: Cell Line

Proper Citation

Ubigen Cat# YC-C094, RRID:CVCL_0161

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0161

Proper Citation: Ubigen Cat# YC-C094, RRID:CVCL_0161

Description: Cell line Ba/F3 is a Factor-dependent cell line with a species of origin Mus musculus (Mouse)

Defining Citation: [PMID:17133113](#), [PMID:25277546](#)

Comments: Caution: Originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse (PubMed=25277546)., Miscellaneous: Direct author submission of STR profile from Neve, Richard M.; STR performed by Labcorp Cell Line Testing., Characteristics: IL3 dependent.

Category: Factor-dependent cell line

Organism: Mus musculus (Mouse)

Name: Ba/F3

Synonyms: BA/F3, BaF3, BAF3, Baf3

Cross References: BTO:BTO_0001516, CLO:CLO_0001842, CLO:CLO_0051421, EFO:EFO_0022749, MCCL:MCC:0000053, BioGRID_ORCS_Cell_line:221, CCRID:1101MOU-PUMC000095, ChEMBL-Cells:ChEMBL3307634, ChEMBL-Targets:ChEMBL614524, CLS:305224, DSMZ:ACC-300, DSMZCellDive:ACC-300, Lonza:693, PRIDE:PXD000461, PubChem_Cell_line:CVCL_0161, RCB:RCB0805, RCB:RCB4476, TOKU-E:3694, TOKU-E:4128, Ubigen:YC-C094, Wikidata:Q54752952

ID: CVCL_0161

Vendor: Ubigen

Catalog Number: YC-C094

Record Creation Time: 20250130T070309+0000

Record Last Update: 20260830T001234+0000

Ratings and Alerts

No rating or validation information has been found for Ba/F3.

No alerts have been found for Ba/F3.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 50 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Junttila MR, et al. (2026) Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non-Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations. Cancer research, 86(3), 759.

Lou E, et al. (2026) Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(24), e12332.

Nishimura M, et al. (2026) Autoinhibition of the mechanosensitive lipid scramblase TMEM63B by its C-terminal tail. The Journal of biological chemistry, 302(7), 113223.

Yemelyanenko J, et al. (2026) C-Terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3. Cancer research, 86(6), 1372.

Zwick M, et al. (2026) FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. Cancer research, 86(2), 367.

Tang Z, et al. (2025) Function-driven design of a surrogate interleukin-2 receptor ligand. FEBS letters.

Huang M, et al. (2025) TTC7A-ALK, a novel ALK fusion variant identified in a patient with metastatic lung adenocarcinoma, exhibits excellent response to crizotinib. Translational oncology, 54, 102345.

Kebenko M, et al. (2025) Downregulation of S6 Kinase and Hedgehog-Gli1 by Inhibition of Fatty Acid Synthase in AML with FLT3-ITD Mutation. *International journal of molecular sciences*, 26(12).

Song Z, et al. (2025) Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle-mediated STING activation. *Cell stem cell*, 32(4), 581.

Lv M, et al. (2025) Protein kinase B inhibitors enhance the sensitivity of translocated promoter region-fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis. *The Journal of international medical research*, 53(8), 3000605251362968.

Zwierenga F, et al. (2025) The influence of ROS1 fusion partners and resistance mechanisms in ROS1-TKI-treated non-small cell lung cancer patients. *Molecular oncology*, 19(11), 3023.

Zhou Y, et al. (2025) Chronic ER Stress Triggers Cell-Surface Chaperones as the Therapeutic Targets of CAR Cells in Acute Myeloid Leukemia. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e11573.

Tangpeerachaikul A, et al. (2025) Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations. *Molecular cancer therapeutics*, 24(7), 1005.

Febres-Aldana CA, et al. (2025) Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. *Cancer discovery*, 15(6), 1141.

Pagliarini RA, et al. (2025) STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 3002.

Kready K, et al. (2025) A long-lasting prolactin stimulates galactopoiesis in mice. *iScience*, 28(8), 113112.

Miyata Y, et al. (2025) Membrane structure-responsive lipid scramblase activity of the TMEM63/OSCA family. *FEBS letters*, 599(5), 656.

Yamazoe S, et al. (2025) Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity. *Journal of medicinal chemistry*, 68(11), 11322.